2017
DOI: 10.1136/jclinpath-2016-204244
|View full text |Cite|
|
Sign up to set email alerts
|

ROS1-1

Abstract: ROS1 is a receptor tyrosine kinase that has recently been shown to undergo gene rearrangements in~1%-2% of non-small cell lung carcinoma (NSCLC) and in a variety of other tumours including cholangiocarcinoma, gastric carcinoma, colorectal carcinoma and in spitzoid neoplasms, glioblastoma and inflammatory myofibroblastic tumours. The ROS1 gene fusion undergoes constitutive activation, regulates cellular proliferation and is implicated in carcinogenesis. ROS1 fusions can be detected by fluorescence in situ hybri… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
7
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 17 publications
(7 citation statements)
references
References 81 publications
0
7
0
Order By: Relevance
“…For optimal clinical efficacy of TRK inhibitors, an effective diagnostic strategy to detect NTRK gene fusions in tumour samples is essential to guide treatment selection. Approaches that may be used to directly or indirectly detect the presence of a gene fusion in clinical tissue samples51 include immunohistochemistry (IHC), fluorescence in situ hybridisation (FISH), reverse transcriptase polymerase chain reaction (RT-PCR) and next-generation sequencing (NGS) using DNA or RNA (table 2). 10 18 32 34 52–58…”
Section: Testing Methods For Trk Fusion Cancersmentioning
confidence: 99%
“…For optimal clinical efficacy of TRK inhibitors, an effective diagnostic strategy to detect NTRK gene fusions in tumour samples is essential to guide treatment selection. Approaches that may be used to directly or indirectly detect the presence of a gene fusion in clinical tissue samples51 include immunohistochemistry (IHC), fluorescence in situ hybridisation (FISH), reverse transcriptase polymerase chain reaction (RT-PCR) and next-generation sequencing (NGS) using DNA or RNA (table 2). 10 18 32 34 52–58…”
Section: Testing Methods For Trk Fusion Cancersmentioning
confidence: 99%
“…Some molecular alterations have gained attention in the last years, specially ROS1 fusions, present in 2–3% of the lung adenocarcinomas, as well as in cholangio, gastric and colonic carcinomas [ 179 ]. They are present in spitzoid neoplasms, glioblastoma multiforme and inflammatory myofibroblastic tumors, too.…”
Section: Tyrosine Kinase Receptor Inhibitors Developed For Cancer mentioning
confidence: 99%
“…Only a few anti-ROS1 antibodies have been validated and recommended for use in daily routine practice [ 41 , 42 , 43 , 44 ]. The D4D6 (Cell Signaling Technology, Leiden, The Netherlands) clone is used by the majority of laboratories [ 38 ].…”
Section: The Therapeutic Targets Identified By Immunohistochemistrmentioning
confidence: 99%